1. Home
  2. RMCO vs MDXH Comparison

RMCO vs MDXH Comparison

Compare RMCO & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royalty Management Holding Corporation

RMCO

Royalty Management Holding Corporation

N/A

Current Price

$2.88

Market Cap

37.9M

Sector

Miscellaneous

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.44

Market Cap

41.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCO
MDXH
Founded
2021
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Multi-Sector Companies
Sector
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
41.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RMCO
MDXH
Price
$2.88
$0.44
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
12.8K
758.2K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
0.35%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$209.10
$30.78
Revenue Next Year
$133.33
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.19
$0.45
52 Week High
$5.00
$5.33

Technical Indicators

Market Signals
Indicator
RMCO
MDXH
Relative Strength Index (RSI) 59.75 18.95
Support Level $2.75 N/A
Resistance Level $3.06 $3.79
Average True Range (ATR) 0.23 0.05
MACD 0.02 0.04
Stochastic Oscillator 94.23 11.12

Price Performance

Historical Comparison
RMCO
MDXH

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: